|Bid||173.05 x 1100|
|Ask||173.64 x 1400|
|Day's range||172.40 - 178.74|
|52-week range||115.03 - 217.25|
|Beta (5Y monthly)||1.71|
|PE ratio (TTM)||6.48|
|Earnings date||23 Feb 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||226.64|
In last-year's difficult market, growth stocks were among the first to suffer. Why should we be confident about growth stocks? Moderna (NASDAQ: MRNA) went from zero product revenue prior to the pandemic to about $18 billion annually over the past two years.
FREMONT, Calif., February 03, 2023--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, and Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the companies have signed a new agreement to continue using the Personalis NeXT Platform® as part of upcoming clinical studies evaluating mRNA-4157/V940, an investigational personalized cancer vaccine, jointly developed by Moderna and Merck, kn
The past three years have been fascinating for Moderna (NASDAQ: MRNA) and its shareholders. Moderna's shares are up by an impressive 731% since early 2020, although its coronavirus-related sales will start falling this year. At this point, it's fair to ask if Moderna can march on and continue delivering market-beating returns, or if the company won't be worth an investment in a post-pandemic world.